Latest Biotech News

Roche has struck an obesity-focused pact with Rona Therapeutics, gaining global rights to a Rona RNA interference program targeting ALK7, a genetically validated obesity and metabolic indication....

Happy Health received FDA clearance for its wearable ring designed to continuously measure blood pressure without a cuff or external calibration. The clearance marks a step for cuffless,...

A phase I trial at Ohio State reported early efficacy for next-generation CAR T cells engineered to target three B-cell proteins and co-stimulated with OX40. In relapsed B-cell blood cancers, the...

MIT researchers unveiled lipid nanoparticles that reprogram natural killer cells inside the body into CAR-bearing cancer killers. In mouse models of melanoma, lymphoma, and autoimmune hepatitis,...

Gladstone Institutes researchers reported discovery of an unusual bacterial immune system—“type VI retrons”—published in Molecular Cell. Unlike conventional defense systems, the mechanism operates...

CDC surveillance data show clinical Candida auris cases climbed from 2,882 in 2022 to 6,197 in 2024—more than doubling in two years—prompting an urgent antimicrobial-resistance warning. The rise...

Researchers reported that oncogenic KRAS reprograms adenosine metabolism by upregulating NT5E and suppressing ADA, creating an immunosuppressive tumor microenvironment. In preclinical models,...

Researchers engineered a cell-penetrating receptor mimic targeting SCARB2 to broadly inhibit EV-A71 and CV-A16, two enteroviruses that can cause severe disease in infants. The work reported...

For the first time, six proteomic aging clocks have been deployed as readouts in a clinical trial, enabling real-world testing of biomarker behavior and performance. The study aims to clarify...

A new NIH proposal would conceal impact scores on grant applications, instead grouping submissions into broad “discussed” and “not discussed” buckets. Experts and scientists criticized the plan as...

Bristol Myers Squibb disclosed mixed Phase 3 results for its idiopathic pulmonary fibrosis therapy admilparant, with only the lower dose meeting the trial’s main objective—intensifying questions...

Enodia Therapeutics and Pfizer inked a research collaboration and licensing deal to discover and develop small-molecule inhibitors of Sec61. Enodia will run discovery and early optimization while...

Roche secured global rights to a Rona Therapeutics RNA interference drug targeting ALK7—adding to a fast-growing ALK7 obesity race that also includes GSK and Arrowhead Pharmaceuticals. Roche will...

New preclinical data indicate KRAS-mutant tumors rewire adenosine metabolism via NT5E upregulation and ADA suppression, creating an immunosuppressive tumor microenvironment that can blunt...

Beam Therapeutics disclosed early Phase 1/2 base editing data on a rare disease program, while also announcing it will collaborate with Enodia—an example of how gene-editing players are pairing...

A study of IDH-wildtype glioblastoma patients found that monocyte recovery during chemoradiotherapy is independently prognostic for longer survival, using a dynamic blood measure rather than a...

Syndax is ending development of Niktimvo in idiopathic pulmonary fibrosis after the therapy failed in a mid-stage trial, an outcome that further narrows the near-term pipeline for IPF and...

A nationwide South Korean study linked opioid prescriptions during pregnancy to higher hospital admission risk in children, with a dose-dependent pattern persisting through age five—adding...

Drug delivery particle engineering is getting fresh translational momentum: The Journal of Pharmaceutical Investigation announced a January 2027 special issue focused on advances in dosage form...

A new audit on AI model maintenance warns that “machine unlearning” can silently degrade performance on rare diagnoses and proposes a safety framework to detect and mitigate spillover risks. In...